Effect of amiloride on lithium-induced chronic nephropathy.

Recruiting

• Conditions: lithium nephropathy; 10029149

• Registration Number: NL-OMON33899
• Lead Sponsor: Sint Elisabeth Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 30

Inclusion Criteria

Patients on chronic lithium therapy and progressive renal function loss, defined as a plasma creatinine concentration increase of at least 10 umol/l/year during at least 5 years, a correlation coefficient of 0.85 on linear regression analysis and a maximum plasma creatinine value of 200 umol/l.

Exclusion Criteria

Inability to give informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The result of combining lithium with amiloride should be reflected in a change<br /><br>in the course of de plasma creatinine concentration (at least cutting in half<br /><br>the slope of the plasma creatinine concentration) within 9 months.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Does not apply.</p><br>